| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.004 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.14 | 8e-05 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.14 | 2e-05 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.002 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.08 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.13 | 6e-05 |